Sequencing Of Agents

CME Available: auau.auanet.org/node/41735

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.

3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.

4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.